Therefore, it is conceivable that several major European and American

[Mst.Rina1R]

Where is the gap in the market now? Qu Zhihao pointed out "early process development" because the concept of OEM manufacturing all over the world is the same, winning by quantity. However, in the pharmaceutical field, mass production is only possible after passing strict review and approval by the U.S. Food and Drug Administration (FDA). , in theory, it is a high-risk, money-burning business. "Pharmaceutical companies have to conduct experiments again and again before passing FDA review to find out the key parameters of the manufacturing process."

CDMO manufacturers currently visible in the market do not prefer to invest in early process development.

Early process development is currently a gap in the CDMO market, and this is an opportunity for Taiwan. .jpg
Qu Zhihao said that early process development is currently a gap in the CDMO market and this is an opportunity for Taiwan.
Picture/Lin Zhiyuan Photography
"What TBMC wants to invest now is the early process development iceland telegram market." Qu Zhihao said that Taiwan's development advantage lies in its smart manufacturing capabilities. It uses all the data accumulated in the past to optimize the process development speed and achieve small-volume and diverse production models. "This is in Taiwan's semiconductor industry. The industry and IT industry have proven it.”

To put it simply, the government now wants to copy the successful model of Taiwan Semiconductor Manufacturing Co., Ltd. (TSMC) to the biotech industry and create the next national protector .

The establishment strategy of TBMC company is based on the successful experience of TSMC. .jpg
TBMC's company establishment strategy is based on the successful experience of TSMC.
Picture/Lin Zhiyuan Photography
TBMC settled in Nangang, aiming to raise more than 4.5 billion in Series A funding
But can the biotechnology and medical industry really become the next national protector? It remains to be verified by time.

In the first phase, TBMC's process development laboratory will be located in Nangang Biotechnology Park, and pharmaceutical factories that comply with GMP (Good Manufacturing Practice) will be stationed in Zhubei Biomedical Park, and will continue to deepen strategic cooperation with National Resilience.

In terms of funding, Qu Zhihao revealed that TBMC's current capital is NT$3.44 billion, and it is expected to launch a Series A fundraiser at NT$20 per share, with a target of more than NT$4.5 billion.